BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 12172549)

  • 1. A leukemogenic twist for GATA1.
    Look AT
    Nat Genet; 2002 Sep; 32(1):83-4. PubMed ID: 12172549
    [No Abstract]   [Full Text] [Related]  

  • 2. Acquired mutations in GATA1 in the megakaryoblastic leukemia of Down syndrome.
    Wechsler J; Greene M; McDevitt MA; Anastasi J; Karp JE; Le Beau MM; Crispino JD
    Nat Genet; 2002 Sep; 32(1):148-52. PubMed ID: 12172547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GATA1--a player in normal and leukemic megakaryopoiesis.
    Hitzler JK
    Pediatr Res; 2002 Dec; 52(6):831. PubMed ID: 12438656
    [No Abstract]   [Full Text] [Related]  

  • 4. Origins of leukaemia in children with Down syndrome.
    Hitzler JK; Zipursky A
    Nat Rev Cancer; 2005 Jan; 5(1):11-20. PubMed ID: 15630411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia.
    Ge Y; Stout ML; Tatman DA; Jensen TL; Buck S; Thomas RL; Ravindranath Y; Matherly LH; Taub JW
    J Natl Cancer Inst; 2005 Feb; 97(3):226-31. PubMed ID: 15687366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prenatal origin of GATA1 mutations may be an initiating step in the development of megakaryocytic leukemia in Down syndrome.
    Taub JW; Mundschau G; Ge Y; Poulik JM; Qureshi F; Jensen T; James SJ; Matherly LH; Wechsler J; Crispino JD
    Blood; 2004 Sep; 104(5):1588-9. PubMed ID: 15317736
    [No Abstract]   [Full Text] [Related]  

  • 7. GATA1 as a new target to detect minimal residual disease in both transient leukemia and megakaryoblastic leukemia of Down syndrome.
    Pine SR; Guo Q; Yin C; Jayabose S; Levendoglu-Tugal O; Ozkaynak MF; Sandoval C
    Leuk Res; 2005 Nov; 29(11):1353-6. PubMed ID: 15916804
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The GATA1 mutation in an adult patient with acute megakaryoblastic leukemia not accompanying Down syndrome.
    Harigae H; Xu G; Sugawara T; Ishikawa I; Toki T; Ito E
    Blood; 2004 Apr; 103(8):3242-3. PubMed ID: 15070711
    [No Abstract]   [Full Text] [Related]  

  • 9. Developmental stage-selective effect of somatically mutated leukemogenic transcription factor GATA1.
    Li Z; Godinho FJ; Klusmann JH; Garriga-Canut M; Yu C; Orkin SH
    Nat Genet; 2005 Jun; 37(6):613-9. PubMed ID: 15895080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tetrasomy 21 transient leukemia with a GATA1 mutation in a phenotypically normal trisomy 21 mosaic infant: case report and review of the literature.
    Sandoval C; Pine SR; Guo Q; Sastry S; Stewart J; Kronn D; Jayabose S
    Pediatr Blood Cancer; 2005 Jan; 44(1):85-91. PubMed ID: 15390279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GATA1 mutation and trisomy 21 are required only in haematopoietic cells for development of transient myeloproliferative disorder.
    Carpenter E; Valverde-Garduno V; Sternberg A; Mitchell C; Roberts I; Vyas P; Vora A
    Br J Haematol; 2005 Feb; 128(4):548-51. PubMed ID: 15686466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fetal origin of the GATA1 mutation in identical twins with transient myeloproliferative disorder and acute megakaryoblastic leukemia accompanying Down syndrome.
    Shimada A; Xu G; Toki T; Kimura H; Hayashi Y; Ito E
    Blood; 2004 Jan; 103(1):366. PubMed ID: 14684662
    [No Abstract]   [Full Text] [Related]  

  • 13. GATA1 mutations in Down syndrome: implications for biology and diagnosis of children with transient myeloproliferative disorder and acute megakaryoblastic leukemia.
    Crispino JD
    Pediatr Blood Cancer; 2005 Jan; 44(1):40-4. PubMed ID: 15390312
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations in exon 2 of GATA1 are early events in megakaryocytic malignancies associated with trisomy 21.
    Rainis L; Bercovich D; Strehl S; Teigler-Schlegel A; Stark B; Trka J; Amariglio N; Biondi A; Muler I; Rechavi G; Kempski H; Haas OA; Izraeli S
    Blood; 2003 Aug; 102(3):981-6. PubMed ID: 12649131
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutations in GATA1 in both transient myeloproliferative disorder and acute megakaryoblastic leukemia of Down syndrome.
    Greene ME; Mundschau G; Wechsler J; McDevitt M; Gamis A; Karp J; Gurbuxani S; Arceci R; Crispino JD
    Blood Cells Mol Dis; 2003; 31(3):351-6. PubMed ID: 14636651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. GATA1 mutations in transient leukemia and acute megakaryoblastic leukemia of Down syndrome.
    Hitzler JK; Cheung J; Li Y; Scherer SW; Zipursky A
    Blood; 2003 Jun; 101(11):4301-4. PubMed ID: 12586620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. GATA 1 mutations as clonal markers of minimal residual disease in acute megakaryoblastic leukemia of Down syndrome--a new tool with significant potential applications.
    Hitzler J; Zipursky A
    Leuk Res; 2005 Nov; 29(11):1239-40. PubMed ID: 15925405
    [No Abstract]   [Full Text] [Related]  

  • 18. [Mutations of erythroid/megakaryocytic transcription factor GATA-1 and leukemia in childhood].
    Ito E
    Rinsho Ketsueki; 2004 Feb; 45(2):108-14. PubMed ID: 15045818
    [No Abstract]   [Full Text] [Related]  

  • 19. Down syndrome and GATA1-related transient leukemia.
    Sandoval C; Pine SR
    J Pediatr; 2007 Mar; 150(3):e34. PubMed ID: 17307526
    [No Abstract]   [Full Text] [Related]  

  • 20. Comprehensive analysis of gene alterations in acute megakaryoblastic leukemia of Down's syndrome.
    Hirose Y; Kudo K; Kiyoi H; Hayashi Y; Naoe T; Kojima S
    Leukemia; 2003 Nov; 17(11):2250-2. PubMed ID: 12931214
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.